Le Lézard
Classified in: Health
Subject: SVY

EU Pharmaceutical Regulations & Strategy Course: Registration Strategy Discussion - Will Brexit Alter this? (London, United Kingdom - October 31, 2019 November 1, 2019)


DUBLIN, Sept. 19, 2019 /PRNewswire/ --  The "EU Pharmaceutical Regulations & Strategy" conference has been added to ResearchAndMarkets.com's offering

Research and Markets Logo

This course will provide an up-to-date overview of the European pharmaceutical regulatory environment, procedures, and obligations

You will learn about the legal basis of regulation, development strategies and the strategic importance of pre-submission actions, the format for presentation of data, how the registration procedures work and post-authorisation strategies and obligations.

The programme will be of value to regulatory affairs personnel and also to those who interact with regulatory personnel in order to understand action timelines and information requirements.

Benefits of attending:

Who Should Attend:

This course will be of particular relevance if you are involved in:

Agenda:

Programme day one

Welcome and introduction

EU regulatory environment: legal basis

Development strategy and pre-submission activities

Case study 1: Submission requirements

The Common Technical Document (CTD)

The EMA

Applying for marketing authorisation in the EU

Case study 2: Registration strategy discussion

Programme day two

Registration procedures

Managing product labelling

Abridged applications

Post-authorisation obligations and strategic considerations

Safety reporting

Licence variations

Strategic considerations

Case study 3: Post-authorisation strategy discussion

Licence renewals

For more information about this conference visit https://www.researchandmarkets.com/r/1lsetc

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

Media Contact:

Research and Markets
Laura Wood, Senior Manager
[email protected]

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

SOURCE Research and Markets


These press releases may also interest you

18 avr 2024
The 31st Canadian Cancer Society (CCS) Daffodil Ball, which took place this evening at Windsor Station in Montreal, raised $1,474,785 to fund innovative research projects and essential support programs for people living with cancer. The largest...

18 avr 2024
The report titled "Clinical Trials Matching Software Market by Functionality (Analytics & Reporting, Compliance Tracking, Data Management), Deployment (Cloud & Web Based, On-Premise), End-Use - Global Forecast 2024-2030" is now available on...

18 avr 2024
South Korea's biotechnology company Hyundai Bioscience (CEO Oh Sang-gi, www.hyundaibioscience.com) announced on April 15 that it would carry out global clinical tests aimed at treating all serotypes of Dengue virus infection....

18 avr 2024
The report titled "Progressive Familial Intrahepatic Cholestasis Treatment Market by Drug Type (Cholestyramine, Rifampicin, Ursodeoxycholic Acid), Distribution Channel (Hospital Pharmacies, Online Pharmacies, Retail Pharmacies), End-Users - Global...

18 avr 2024
RevolKa Ltd. (Norio Hamamatsu, President & CEO), a venture-backed biotech company providing a game-changing protein engineering technology platform and La Jolla Institute for Immunology (LJI) (Erica Saphire, President & CEO) agreed to start a...

18 avr 2024
Takeda (TSE:4502/NYSE:TAK) today announced that the U.S. Food and Drug Administration (FDA) has approved ENTYVIO® (vedolizumab) subcutaneous (SC) administration for maintenance therapy in adults with moderately to severely active Crohn's disease (CD)...



News published on and distributed by: